Ken Griffin Seres Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 36,900 shares of MCRB stock, worth $26,568. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,900
Previous 74,000
50.14%
Holding current value
$26,568
Previous $103,000
72.82%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding MCRB
# of Institutions
100Shares Held
62.7MCall Options Held
36.9KPut Options Held
476K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$16.6 Million1.17% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$4.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.73MShares$4.85 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT5.43MShares$3.91 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.13MShares$1.54 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $89.3M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...